[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100402427":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":41,"centralContacts":46,"locations":56,"responsibleParty":76,"collaborators":50,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":50,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":50,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":59,"whyStopped":50,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"University of Athens","OTHER",[8,15,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"olive extract 1 - olivomed","ACTIVE_COMPARATOR","15 patients will be randomized to receive two Olivomed soft capsules bid for one month (5 mg hydroxytyrosol po twice daily) and then they will be crossed over to treatment placebo for another one month.",[13,14],"Dietary Supplement: Olivomed (capsules containing hydroxytyrosol)","Dietary Supplement: OlivomedSmart - Capsules containing - combination of Oleuropein (OL), Hydroxytyrosol (HT), Oleocanthal (OC) - (OL:HT:OC 2:1:3), (5 mg HT bid).",{"label":16,"type":17,"description":18,"interventionNames":19},"placebo 1","PLACEBO_COMPARATOR","15 patients will be randomized to receive two placebo soft capsules bid for one month. Then they will be crossed over to receive two Olivomed soft capsules bid for oen month (5 mg hydroxytyrosol po twice daily)",[13,14],{"label":21,"type":10,"description":22,"interventionNames":23},"olive extract 2 - olivomedSmart","15 patients will be randomized to receive two soft capsules containing OL:HT:OC (2:1:3) bid for one month (5 mg hydroxytyrosol po twice daily) and then they will be crossed over to treatment placebo for another one month.",[13,14],{"label":25,"type":17,"description":26,"interventionNames":27},"placebo2","15 patients will be randomized to receive two placebo soft capsules bid for one month. Then they will be crossed over to receive two soft capsules containing OL:HT:OC (2:1:3) bid for one month (5 mg hydroxytyrosol po twice daily) bid for one month.",[13,14],[29,36],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DIETARY_SUPPLEMENT","Olivomed (capsules containing hydroxytyrosol)","patients with stable coronary artery disease will be randomised to Olivomed or placebo for one month and then they will be crossed over to the alternate treatment for one month.",[9,21,16,25],[35],"placebo soft capsules",{"type":30,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"OlivomedSmart - Capsules containing - combination of Oleuropein (OL), Hydroxytyrosol (HT), Oleocanthal (OC) - (OL:HT:OC 2:1:3), (5 mg HT bid).","patients with stable coronary artery disease will be randomised to combination of OL, HT, OC or placebo for one month and then they will be crossed over to the alternate treatment for one month.",[9,21,16,25],[35],[42],{"name":43,"affiliation":44,"role":45},"Ignatios Ikonomidis","2nd Cardiology Department, National and Kapodistrian University of Athens, Attikon General Hospital","PRINCIPAL_INVESTIGATOR",[47,52],{"name":43,"role":48,"phone":49,"phoneExt":50,"email":51},"CONTACT","+302105832187",null,"ignoik@gmail.com",{"name":53,"role":48,"phone":54,"phoneExt":50,"email":55},"Konstantinos Katogiannis","+306938165687","kenndj89@gmail.com",[57],{"facility":58,"status":59,"city":60,"state":61,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"\"Attikon\" University General Hospital","RECRUITING","Athens","Attica","12462","Greece","GR",{"type":66,"coordinates":67},"Point",[68,69],23.72784,37.98376,{"lat":69,"lon":68},[72,75],{"name":73,"role":48,"phone":74,"phoneExt":50,"email":50},"Ignatios Ikonomidis, MD","00302105832187",{"name":73,"role":45,"phone":50,"phoneExt":50,"email":50},{"type":45,"investigatorFullName":43,"investigatorTitle":77,"investigatorAffiliation":5,"oldNameTitle":50,"oldOrganization":50},"Professor of Cardiology","100402427","effect-of-olivomed-olive-extract-on-endothelial-cardiac-and-vascular-function-100402427",false,"NCT04520126","Effect of Olivomed (Olive Extract) on Endothelial, Cardiac and Vascular Function","Effect of Olivomed (Olive Extract) on Endothelial, Cardiac and Vascular Function of Patients With Stable Coronary Artery Disease","Inclusion Criteria:\n\n1. Age \\\u003C70 years\n2. Stable coronary heart disease\n3. Patients with acute coronary syndrome who have undergone percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), 2 months must have passed since the incident\n4. High LDL levels, low HDL, high triglycerides\n\nExclusion Criteria:\n\n1. Age\\> 70 years\n2. Patient with diabetes\n3. Patient with hypertension\n4. Patient with liver disease\n5. Patient with thyroid disease\n6. Patient with active malignancy\n7. Patient with a disease that affects inflammatory markers (rheumatic diseases, etc.)\n8. Patient with chronic renal failure (creatinine\\> 2 mg \u002F dl)\n9. Patient treated chronically with corticosteroids\n10. Patient who has joined a weight loss program or any dietary intervention or intensive exercise programme within the previous 2 months or consumes multivitamin preparations with antioxidant properties.","ALL","18 Years","70 Years",{"count":89,"type":90},30,"ESTIMATED","INTERVENTIONAL",[93],"NA","Olive extracts are considered to have antioxidant properties. The investigators will study the effect of olive extracts containing hydroxytyrosol (HT)-olivomed and combination of Oleuropein (OL), Hydroxytyrosol (HT), Oleocanthal (OC) - olivomedSmart on endothelial, cardiac and vascular function in patients with coronary artery disease .",[96],"Coronary Artery Disease",[98],"olive oil, myocardial deformation, glycocalyx","2024-05-28",{"date":101,"type":102},"2024-05-29","ACTUAL",{"date":104,"type":102},"2020-12-01",{"date":106,"type":90},"2026-08-01",{"name":5,"class":6},1]